Clinical and Immunological Analysis of Cutaneous Leishmaniasis before and after Different Treatments

Table 1

Lesions in patients with primary infection and their treatment.

(a)

Localization of 170 lesions, 𝑛= lesions, 𝑛/170 = (%)
Right leg	Left leg	Right arm	Left arm	Abdomen	Thorax	Head
69 (40.58)	43 (25.29)	22 (12.94)	15 (8.82)	6 (3.52)	7 (4.11)	8 (4.70)

(b)

Treatments in 87 patients with primary lesions, 𝑛= patients, 𝑛/87 = (%)
Treatments	Doses	Remission	Remission weeks
SR^a 31, (35.63)	None	(100%)	7.41±2.71
Glu^b 37, (42.52)	24.54±15.07	35/37, (94.59%)	9.02±5.04
VT^c 19, (21.83)	6.36±3.41	(100%)	7.40±2.70

aSR: spontaneous remission. ^bGlu: meglumine antimoniate or Glucantime.
cVT: Leishmania amastigotes (La, Lv, Lb, and Lch) after TLCK treatment and NP-40 extraction.